AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 72 min read$JNJ

Forminard Elizabeth sold $4.1M of JNJ

Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares of JOHNSON & JOHNSON (JNJ) at an average of $257.00 ($255.93–$257.76, $4.09M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Forminard Elizabeth
Published Aug 7, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the company’s EVP and Chief Legal Officer, including trade dates, share count, and total value.

02

Market read

Traders may note insider selling, but the disclosure does not provide new operational or financial guidance for JNJ.

03

What to watch

The filing does not disclose intent, tax context, or whether additional sales occurred around the same period; without that, price reaction should be muted.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after-hours; reflects trades dated 2026-08-06

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson disclosed via Form 4 that EVP Chief Legal Officer Forminard Elizabeth sold 15,918 shares for about $4.09M on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 provides transaction details but does not indicate new corporate guidance, litigation, or operational changes. The sale size is moderate relative to JNJ and lacks a stated catalyst in the filing.

Market effects

Sector

Insider selling in a mega-cap healthcare name is not a reliable sector signal without broader pattern or sector-specific regulatory/earnings catalysts.

Regional

No clear regional spillover; this is company-specific insider transaction disclosure.

Global

Minimal global relevance; JNJ is widely held, but this filing alone does not change global fundamentals.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be misread as bearish; executives may sell for diversification or tax reasons unrelated to outlook.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Forminard Elizabeth

    EVP, Chief Legal Officer who sold shares via open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JNJ insider trading history →

Related articles

SEP 25
$JNJHigh

The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement

Johnson & Johnson (JNJ) extended its 64-year dividend growth streak with a 3.1% quarterly raise, supported by projected $21 billion in free cash flow. The company's oncology drugs, like CARVYKTI and TREMFYA, offset losses from Stelara biosimilars. JNJ's dividend yield is 1.94%, and shares are up 31.11% year-to-date. The company aims for a 65th consecutive hike in 2027, subject to free cash flow and litigation risks.

aol.com2 min
SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min